By evaluating protein biomarkers alongside patient demographic information, TargetDx Laboratory provides a risk assessment for early-stage lung cancer with high sensitivity and specificity. The company has obtained patents and published research on novel markers related to lung cancer, as well as validated known markers for diagnostic use. Their flagship product, the LCDT1 (Lung Cancer Detection Test-1), is a simple blood test that accurately detects early-stage Non-Small Cell Lung Cancer. Additionally, TargetDx Laboratory has expanded its services to include accurate COVID-19 viral and antibody testing, contributing to the fight against the pandemic. They are a CLIA Certified Laboratory for High Complexity Testing, ensuring quality and reliability in their diagnostic services.